| Literature DB >> 33937316 |
Laura E Geldmaker1, Amanda E Kahn1, Kevin A Parikh1, Ivan E Porter2, Daniela A Haehn1, Essa M Bajalia1, Qihui Zhai3, Colleen T Ball4, David D Thiel1.
Abstract
Background: To evaluate robotic-assisted partial nephrectomy (RAPN) renal outcomes associated with ancillary pathology findings in non-neoplastic renal parenchymal tissue.Entities:
Keywords: arteriosclerosis; fibrosis; glomerulosclerosis; histologic abnormality; robotic-assisted partial nephrectomy
Year: 2021 PMID: 33937316 PMCID: PMC8085594 DOI: 10.3389/fsurg.2021.652524
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Non-neoplastic renal tissue from a patient with GD on 200× magnification. Two glomeruli were sclerotic, a typical histologic feature for glomeruli disease.
Figure 2Non-neoplastic renal tissue on 100× of a patient with TD. Pictured here is interstitial disease, evidenced by the interstitial fibrosis and chronic inflammation.
Figure 3The non-neoplastic renal tissue of a patient with VD on 200× magnification. The figure shows renal arteriolar stenosis, evidenced by the narrowing of the vascular lumen and thickened vascular wall.
Patient characteristics.
| Median age (range), years | 63 (31–84) |
| 31–64 years | 122 (55.0%) |
| 65–84 years | 100 (45.0%) |
| Female | 77 (34.7%) |
| Male | 145 (65.3%) |
| Median body mass index (range), kg/m2 | 29.8 (19.0–55.1) |
| 19.0–24.9 kg/m2 | 34 (15.3%) |
| 25.0–29.9 kg/m2 | 80 (36.0%) |
| 30.0–55.1 kg/m2 | 108 (48.6%) |
| White | 188 (84.7%) |
| Black | 25 (11.3%) |
| Asian | 3 (1.4%) |
| Unknown | 6 (2.7%) |
| No | 69 (31.1%) |
| Yes | 153 (68.9%) |
| No | 172 (77.5%) |
| Yes | 50 (22.5%) |
| 4–6 | 51 (23.0%) |
| 7–9 | 123 (55.4%) |
| 10–12 | 48 (21.6%) |
| 0–3 Low grade | 154 (69.4%) |
| 4–5 High grade | 68 (30.6%) |
| Median eGFR (range), mL/min/1.73 m2 | 75 (12–120) |
| 60–144 mL/min/1.73 m2 | 179 (80.6%) |
| 12–59 mL/min/1.73 m2 | 43 (19.4%) |
| Negative | 158 (71.2%) |
| Moderate | 18 (8.1%) |
| Global | 46 (20.7%) |
| Absent | 186 (83.8%) |
| Present | 36 (16.2%) |
| Absent | 93 (41.9%) |
| Mild | 45 (20.3%) |
| Moderate | 76 (34.2%) |
| Severe | 8 (3.6%) |
| 0 | 81 (36.5%) |
| 1 | 67 (30.2%) |
| 2 | 59 (26.6%) |
| 3 | 15 (6.8%) |
MAP, Mayo Adhesive Probability; eGFR, estimated glomerular filtration rate. The sample median (minimum, maximum) is shown for numeric variables. Number (percentage of patients) is shown for categorical variables.
Associations of patient characteristics with the number of ancillary pathology factors.
| Age, No. (%) | 0.018 | ||||
| 31–64 y | 53 (65%) | 31 (46%) | 33 (56%) | 5 (33%) | |
| 65–84 y | 28 (35%) | 36 (54%) | 26 (44%) | 10 (67%) | |
| Sex, No. (%) | 0.81 | ||||
| Female | 28 (35%) | 25 (37%) | 19 (32%) | 5 (33%) | |
| Male | 53 (65%) | 42 (63%) | 40 (68%) | 10 (67%) | |
| BMI, No. (%) | 0.21 | ||||
| 19.0–24.9 kg/m2 | 15 (19%) | 9 (13%) | 7 (12%) | 3 (20%) | |
| 25.0–29.9 kg/m2 | 30 (37%) | 29 (43%) | 16 (27%) | 5 (33%) | |
| 30.0–55.1 kg/m2 | 36 (44%) | 29 (43%) | 36 (61%) | 7 (47%) | |
| Race, No. (%) | 0.90 | ||||
| Black | 9 (11%) | 8 (12%) | 7 (12%) | 1 (7%) | |
| Non-black | 72 (89%) | 59 (88%) | 52 (88%) | 14 (93%) | |
| Hypertension, No. (%) | <0.001 | ||||
| No | 38 (47%) | 18 (27%) | 10 (17%) | 3 (20%) | |
| Yes | 43 (53%) | 49 (73%) | 49 (83%) | 12 (80%) | |
| Diabetes, No. (%) | 0.92 | ||||
| No | 62 (77%) | 52 (78%) | 48 (81%) | 10 (67%) | |
| Yes | 19 (23%) | 15 (22%) | 11 (19%) | 5 (33%) | |
| R.E.N.A.L., No. (%) | 0.81 | ||||
| 4–6 | 20 (25%) | 13 (19%) | 13 (22%) | 5 (33%) | |
| 7–9 | 44 (54%) | 40 (60%) | 34 (58%) | 5 (33%) | |
| 10–12 | 17 (21%) | 14 (21%) | 12 (20%) | 5 (33%) | |
| MAP score, No. (%) | 0.047 | ||||
| Low grade | 61 (75%) | 49 (73%) | 34 (58%) | 10 (67%) | |
| High grade | 20 (25%) | 18 (27%) | 25 (42%) | 5 (33%) | |
| eGFR, No. (%) | 0.35 | ||||
| 12–59 mL/min | 13 (16%) | 13 (19%) | 15 (25%) | 2 (13%) | |
| 60–144 mL/min | 68 (84%) | 54 (81%) | 44 (75%) | 13 (87%) | |
| Pathology, No. (%) | 0.18 | ||||
| Benign | 8 (10%) | 9 (13%) | 8 (14%) | 4 (27%) | |
| Malignant | 73 (90%) | 58 (87%) | 51 (86%) | 11 (73%) | |
For continuous variable (age, BMI, and eGFR), P-values were based on the correlations with the continuous variable; however, we report the number and percentage of patients of pre-specified clinical categories for ease of interpretation. Race was categorized as black or non-black; the non-black race category included white (n = 188), Asian (n = 3), and unknown (n = 6).
Ancillary pathology factors and kidney function before and after robotic assisted partial nephrectomy.
| Glomerular disease | Median (range) | Median (range) | Median (range) | Fraction (%) | Median (range) | Median (range) | Fraction (%) | |
| Negative | 158 | 76.0 (12.1–119.7) | −9.4 (−39.1–20.5) | −12.0 (−45.0–28.5) | 84/146 (57.5%) | −9.4 (−39.1–20.2) | −12.0 (−45.0–28.5) | 70/119 (58.8%) |
| Moderate | 18 | 72.6 (16.0–111.0) | −11.1 (−66.6–0.5) | −17.8 (−99.1–3.3) | 11/16 (68.8%) | −13.4 (−27.3–0.0) | −18.3 (−32.0–0.0) | 11/13 (84.6%) |
| Global | 46 | 73.1 (44.3–105.9) | −7.2 (−25.7–15.4) | −12.0 (−36.4–17.5) | 21/50 (52.5%) | −9.1 (−28.8–0.0) | −10.9 (−36.4–0.0) | 13/25 (52.0%) |
| Absent | 186 | 75.4 (12.1–119.7) | −9.5 (−66.6–20.5) | −12.0 (−99.1–28.5) | 100/169 (59.2%) | −9.4 (−39.1–20.2) | −12.0 (−45.0–28.5) | 80/135 (59.2%) |
| Present | 36 | 72.0 (16.0–111.2) | −6.2 (−30.5–8.7) | −10.0 (−40.9–12.2) | 16/33 (48.5%) | −10.0 (−25.5–7.1) | −16.0 (−31.3–11.1) | 16/22 (72.7%) |
| Absent | 93 | 75.4 (12.1–119.7) | −7.9 (−39.1–20.5) | −12.0 (−45.0–28.5) | 47/87 (54.0%) | −8.6 (−39.1–14.1) | −11.4 (−45.0–17.5) | 40/72 (55.6%) |
| Mild | 45 | 82.6 (43.6–111.2) | −9.2 (−27.1–20.5) | −10.9 (−36.4–28.5) | 23/40 (57.5%) | −10.2 (−37.3–12.4) | −13.3 (−42.1–28.5) | 19/29 (65.5%) |
| Moderate | 76 | 71.7 (16.0–111.5) | −9.2 (−66.6–15.0) | −15.9 (−99.1–22.4) | 41/67 (61.2%) | −9.5 (−29.7–20.2) | −15.9 (−35.9–23.6) | 33/53 (62.3%) |
| Severe | 8 | 62.1 (39.9–92.9) | −12.0 (−20.0–4.5) | −19.8 (−27.7–9.4) | 5/8 (62.5%) | −15.6 (−27.3–0.0) | −18.3 (−29.4–0.0) | 2/3 (66.7%) |
| 0 | 81 | 76.6 (12.1–119.7) | −8.0 (−39.1–13.5) | −10.9 (−45.0–28.5) | 39/75 (52.0%) | −8.6 (−39.1–14.1) | −10.9 (−45.0–17.5) | 34/62 (54.8%) |
| 1 | 67 | 74.6 (28.7–111.5) | −10.4 (−34.8–20.5) | −14.9 (−44.0–28.5) | 42/63 (66.7%) | −9.5 (−37.3–20.2) | −13.3 (−42.1–28.5) | 33/51 (64.7%) |
| 2 | 59 | 77.0 (41.2–111.2) | −8.6 (−66.6–15.4) | −13.7 (−99.1–17.5) | 30/50 (60.0%) | −9.7 (−28.8–7.1) | −14.9 (−36.4–11.1) | 21/36 (58.3%) |
| 3 | 15 | 71.6 (16.0–95.8) | −2.0 (−27.9–8.7) | −2.4 (−40.9–12.2) | 5/14 (35.7%) | −10.0 (−21.3–0.0) | −19.0 (−31.3–0.0) | 6/8 (75.0%) |
eGFR, estimated glomerular filtration rate (ml/kg/1.73 m.
Associations of ancillary pathology factors with change in estimated glomerular filtration rate (eGFR) after RAPN.
| Glomerular disease (moderate or global vs. negative) | 0.4 (−3.0, 3.8) | 0.82 | −0.9 (−4.8, 3.1) | 0.67 |
| Tubulo interstitial disease (present vs. absent) | 1.6 (−2.6, 5.9) | 0.44 | 0.2 (−4.7, 5.0) | 0.95 |
| Vascular disease (moderate-to-severe vs. mild or absent) | −3.4 (−6.6, −0.2) | 0.036 | 0.0 (−3.5, 3.6) | 0.99 |
The difference in mean change in eGFR at 1 and 6 months after RAPN were estimated from longitudinal mixed effects regression models with patient-specific random effects for intercepts (pre-RAPN eGFR) and slopes (change in eGFR post-RAPN) using stabilized inverse probability weighting. All models included indicator variables for each post-operative time point. Pre-RAPN eGFR and changes in eGFR were modeled with the given ancillary pathology factor. Post-operative changes in eGFR were additionally modeled with warm ischemia time and operative time.